Literature DB >> 6379852

Biochemical markers in non-Hodgkin's lymphoma stages III and IV and prognosis: a multivariate analysis.

H Hagberg, B Glimelius, S Gronowitz, A Killander, C Källander, T Schröder.   

Abstract

The prognostic value of different pretreatment laboratory and clinical findings at diagnosis was assessed in a series of 141 patients with generalized non-Hodgkin's lymphoma. Univariate and multivariate survival analysis (Cox's regression model) was performed, using serum analysis of deoxythymidine kinase (S-TK), beta 2-microglobulin, lactic dehydrogenase, alpha 1-acid glycoprotein = orosomucoid (S-alpha 1 AGP), haptoglobin and ferritin. In addition, Hb and the erythrocyte sedimentation rate (ESR) were measured. The clinical variables were age, presence or absence of B-symptoms, histopathology ('low-grade'; 'intermediate grade' and 'high-grade' malignancy) and bone marrow involvement. Of the 8 biochemical markers, all except Hb and the ESR showed a significant relationship to survival. Among the clinical variables, this finding was made for B-symptoms and histopathology. Using a multivariate analysis on all variables, S-TK was found to be the best factor for predicting duration of survival. The only significant additional information was provided by S-alpha 1 AGP. When only the clinical variables were taken into account, it was found that histopathology added significant information to that yielded by B-symptoms in the prediction of the survival time. When the biochemical variables were added to this model, only S-TK was of significant additional prognostic value.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6379852     DOI: 10.1111/j.1600-0609.1984.tb02211.x

Source DB:  PubMed          Journal:  Scand J Haematol        ISSN: 0036-553X


  6 in total

Review 1.  Thymidine kinase: a tumor marker with prognostic value for non-Hodgkin's lymphoma and a broad range of potential clinical applications.

Authors:  M Hallek; L Wanders; S Strohmeyer; B Emmerich
Journal:  Ann Hematol       Date:  1992-07       Impact factor: 3.673

2.  Serum thymidine kinase in diagnosis and follow-up of the small cell carcinoma of the lung.

Authors:  V Abbasciano; L Graziano; D Arcudi; G Felisatti; A R Cavallini; M G Reali; N Calia; S Campi; C Guglielmini
Journal:  Med Oncol Tumor Pharmacother       Date:  1991

3.  Haptoglobin-related protein as a serum marker in malignant lymphoma.

Authors:  R Epelbaum; C Shalitin; R Segal; C Valansi; I Arselan; D Faraggi; M Leviov; M Ben-Shahar; N Haim
Journal:  Pathol Oncol Res       Date:  1998       Impact factor: 3.201

4.  Activity of serum thymidine kinase in non-Hodgkin lymphoma: relationship to other prognostic factors.

Authors:  M Hallek; B Emmerich; S Strohmeyer; R Busch; A Reichle; R Senekowitsch
Journal:  Klin Wochenschr       Date:  1988-08-15

5.  Elevated serum thymidine kinase activity in patients with acute viral hepatitis.

Authors:  K Tanaka; T Sishido; M Morimoto; S Inoue; Y Takamura; M Masumura
Journal:  Gastroenterol Jpn       Date:  1993-02

6.  Deoxythymidine kinase in the tumour cells and serum of patients with non-Hodgkin lymphomas.

Authors:  S Rehn; J S Gronowitz; C Källander; C Sundström; B Glimelius
Journal:  Br J Cancer       Date:  1995-05       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.